A study on barriers and facilitators for G6PD test implementation [36] identified three main barriers: perceived low risk of haemolysis, wrong perception of P. vivax malaria as a benign condition, and the cost of routine testing as part of the healthcare attention of malaria patients. Here, G6PD is linked to malaria.